Loading...
Helicobacter pylori infection is associated with atrophic gastritis, which can progress to gastric cancer in some patients. Proton-pump inhibitor (PPI) use has also been associated with atrophic gastritis in some studies. In the current retrospective cohort study, investigators evaluated the association between PPI use and gastric cancer in over 60,000 patients treated with clarithromycin-based triple therapy for H. pylori infection in Hong Kong. Approximately 5% of patients were prescribed PPIs after H. pylori therapy (median duration of PPI use, 3 years). Results were as follows:
During a median follow-up of 8 years, gastric cancer incidence was 0.2%.
A higher percentage of patients on chronic PPI therapy (weekly use or more) developed gast…